The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis
# Background Inhaled hypertonic saline (HS) is an effective mucolytic agent in patients with cystic fibrosis (CF). However, adverse events can impair the clinical utility of hypertonic saline (HS) in this patient population. In this study, we aimed to investigate the effectiveness of hyaluronic aci...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Canadian Society of Respiratory Therapists
2023-10-01
|
| Series: | Canadian Journal of Respiratory Therapy |
| Online Access: | https://doi.org/10.29390/001c.89093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857497803325440 |
|---|---|
| author | Sana Arshid Saad Ehsan Ullah Junaid Imran Meeran Asher Syed Aakash Choradia Nicole Gousy Sukhman Boparai Mudassir Shoaib Bidhan Bikram Shah Aadarsh Netha |
| author_facet | Sana Arshid Saad Ehsan Ullah Junaid Imran Meeran Asher Syed Aakash Choradia Nicole Gousy Sukhman Boparai Mudassir Shoaib Bidhan Bikram Shah Aadarsh Netha |
| author_sort | Sana Arshid |
| collection | DOAJ |
| description | # Background
Inhaled hypertonic saline (HS) is an effective mucolytic agent in patients with cystic fibrosis (CF). However, adverse events can impair the clinical utility of hypertonic saline (HS) in this patient population. In this study, we aimed to investigate the effectiveness of hyaluronic acid (HA) in reducing these adverse events.
# Methods
A literature search was conducted across three electronic databases (Medline, Cochrane Central, and EMBASE) from inception through February 2023. Randomized controlled trials (RCTs) assessing the impact of hyaluronic acid (HA) in reducing adverse events in patients taking hypertonic saline (HS) for CF were included in the analysis. Outcomes of interest included cough, throat irritation, unpleasant taste, and FEV1. Evaluations were reported as risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CI). The Cochrane Risk of Bias Tool (CRBT) was employed to assess the quality of RCTs. The New Castle Ottawa Scale was used to assess the quality of observational studies.
# Results
From the 1960 articles retrieved from the initial search, five relevant studies (n=236 patients) were included in the final analysis. Compared with patients only on HS, patients with HS and HA were significantly less likely to experience cough (RR: 0.45; 95% CI, 0.28--0.72, *p*=0.001), throat irritation (RR: 0.43; 95% CI, 0.22--0.81, *p*= 0.009), and unpleasant smell (RR: 0.43; 95% CI, 0.23 -- 0.80, *p*=0.09). In addition, patients with HS with HA had significantly less forced expiratory volume (FEV1) (MD: -2.97; 95% CI, -3.79---2.15, *p*=0.52) compared to patients only on HS.
# Discussion
The addition of HA to HS was linked to a better tolerability profile. When HS was coupled with HA, there was a reduction in all side effects. This may permit tolerance of the medication in otherwise difficult patients, improve adherence to patients receiving frequent inhalations, and improve therapeutic outcomes.
# Conclusion
The addition of HA is advantageous in CF patients who require continuous HS therapy and have previously shown poor tolerance to therapy. |
| format | Article |
| id | doaj-art-65d0ae564e0945ba881714d991b195b0 |
| institution | Kabale University |
| issn | 2368-6820 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | Canadian Society of Respiratory Therapists |
| record_format | Article |
| series | Canadian Journal of Respiratory Therapy |
| spelling | doaj-art-65d0ae564e0945ba881714d991b195b02025-02-11T20:30:53ZengCanadian Society of Respiratory TherapistsCanadian Journal of Respiratory Therapy2368-68202023-10-0159The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysisSana ArshidSaad Ehsan UllahJunaid ImranMeeran Asher SyedAakash ChoradiaNicole GousySukhman BoparaiMudassir ShoaibBidhan Bikram ShahAadarsh Netha# Background Inhaled hypertonic saline (HS) is an effective mucolytic agent in patients with cystic fibrosis (CF). However, adverse events can impair the clinical utility of hypertonic saline (HS) in this patient population. In this study, we aimed to investigate the effectiveness of hyaluronic acid (HA) in reducing these adverse events. # Methods A literature search was conducted across three electronic databases (Medline, Cochrane Central, and EMBASE) from inception through February 2023. Randomized controlled trials (RCTs) assessing the impact of hyaluronic acid (HA) in reducing adverse events in patients taking hypertonic saline (HS) for CF were included in the analysis. Outcomes of interest included cough, throat irritation, unpleasant taste, and FEV1. Evaluations were reported as risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CI). The Cochrane Risk of Bias Tool (CRBT) was employed to assess the quality of RCTs. The New Castle Ottawa Scale was used to assess the quality of observational studies. # Results From the 1960 articles retrieved from the initial search, five relevant studies (n=236 patients) were included in the final analysis. Compared with patients only on HS, patients with HS and HA were significantly less likely to experience cough (RR: 0.45; 95% CI, 0.28--0.72, *p*=0.001), throat irritation (RR: 0.43; 95% CI, 0.22--0.81, *p*= 0.009), and unpleasant smell (RR: 0.43; 95% CI, 0.23 -- 0.80, *p*=0.09). In addition, patients with HS with HA had significantly less forced expiratory volume (FEV1) (MD: -2.97; 95% CI, -3.79---2.15, *p*=0.52) compared to patients only on HS. # Discussion The addition of HA to HS was linked to a better tolerability profile. When HS was coupled with HA, there was a reduction in all side effects. This may permit tolerance of the medication in otherwise difficult patients, improve adherence to patients receiving frequent inhalations, and improve therapeutic outcomes. # Conclusion The addition of HA is advantageous in CF patients who require continuous HS therapy and have previously shown poor tolerance to therapy.https://doi.org/10.29390/001c.89093 |
| spellingShingle | Sana Arshid Saad Ehsan Ullah Junaid Imran Meeran Asher Syed Aakash Choradia Nicole Gousy Sukhman Boparai Mudassir Shoaib Bidhan Bikram Shah Aadarsh Netha The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis Canadian Journal of Respiratory Therapy |
| title | The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis |
| title_full | The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis |
| title_fullStr | The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis |
| title_full_unstemmed | The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis |
| title_short | The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis |
| title_sort | effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis a systematic review and meta analysis |
| url | https://doi.org/10.29390/001c.89093 |
| work_keys_str_mv | AT sanaarshid theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT saadehsanullah theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT junaidimran theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT meeranashersyed theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT aakashchoradia theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT nicolegousy theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT sukhmanboparai theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT mudassirshoaib theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT bidhanbikramshah theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT aadarshnetha theeffectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT sanaarshid effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT saadehsanullah effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT junaidimran effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT meeranashersyed effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT aakashchoradia effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT nicolegousy effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT sukhmanboparai effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT mudassirshoaib effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT bidhanbikramshah effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis AT aadarshnetha effectivenessofhyaluronicacidinreducingadverseeffectsassociatedwithinhaledhypertonicsalinetherapyinpatientswithcysticfibrosisasystematicreviewandmetaanalysis |